Keywords: Watson, HRA Pharma, Ulipristal, Contraceptive, Abbott Labs, Pierre Fabre, Monoclonal antibody, Licensing, Cancer
Watson gains exclusive US rights to HRA Pharma’s ulipristal and Abbott makes deal with Fabre for MAb
Article | 02 February 2010
US drugmaker Watson Pharmaceuticals entered an exclusive licensing agreement to become the commercial partner for ulipristal acetate (UPA), a selective ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
